Journal of Clinical Oncology

The cognitive load of inpatient consults involving immune-related adverse events.

Journal of Clinical Oncology

Sam Brondfield, Jordyn Silverstein, Kimberly de Dios, Zoe Quandt

Delayed immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors.

Journal of Clinical Oncology

Saya Jacob, Zoe Quandt, Michelle E. Melisko, Melanie Majure, Amy Jo Chien, Anne Hudson Blaes, Diane Heditsian, Laura Esserman, Hope S. Rugo

Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) treated with alpelisib (ALP).

Journal of Clinical Oncology

Emily J. Gallagher, Heather Moore, Mario E. Lacouture, Susan Faye Dent, Azeez Farooki, Marcus D. Goncalves, Claudine Isaacs, Abigail Johnston, Dejan Juric, Zoe Quandt, Laura Spring, Brian Berman, Melanie Decker, Gabriel N. Hortobagyi, Benjamin Kaffenberger, Bernice Y. Kwong, Timothy J. Pluard, Ruta D. Rao, Lee S. Schwartzberg, Michael S. Broder

Immune checkpoint inhibitor–induced diabetes mellitus across NCI trials.

Journal of Clinical Oncology

Zoe E. Quandt, Vanessa Hill, Joe E. Dib, Jason Burian, Sapir Tessler, Abdul Rafeh Naqash, Mark S Anderson, Megan Othus, Elad Sharon

Evaluating survival following severe immune-related adverse events requiring hospitalization.

Journal of Clinical Oncology

Francis Wright, Daniel Myung Kim, Jordyn Silverstein, Michelle Wang, Kimberly de Dios, Arabella Young, Zoe E. Quandt, Sam Brondfield

Phase 2 trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Clinical outcomes and biomarker analyses.

Journal of Clinical Oncology

Robin Kate Kelley, Emily Mitchell, Spencer Behr, Jimmy Hwang, Bridget Keenan, Sarah E Umetsu, John Dozier Gordan, Andrew H. Ko, Pelin Cinar, Chloe Evelyn Atreya, Katherine Van Loon, Thomas Weber, Zoe Ngo, Zoe E. Quandt, Chienying Liu, Alan P. Venook, Lawrence Fong

Phase 2 trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Clinical outcomes and biomarker analyses.

Journal of Clinical Oncology

Robin Kate Kelley, Emily Mitchell, Spencer Behr, Jimmy Hwang, Bridget Keenan, Sarah E Umetsu, John Dozier Gordan, Andrew H. Ko, Pelin Cinar, Chloe Evelyn Atreya, Katherine Van Loon, Thomas Weber, Zoe Ngo, Zoe E. Quandt, Chienying Liu, Alan P. Venook, Lawrence Fong

Phase II trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC).

Journal of Clinical Oncology

Robin Kate Kelley, Emily Mitchell, Spencer Behr, Jimmy Hwang, Bridget Keenan, Alexander Cheung, John Dozier Gordan, Andrew H. Ko, Pelin Cinar, Chloe Evelyn Atreya, Katherine Van Loon, Thomas Weber, Zoe Ngo, Zoe E. Quandt, Chienying Liu, Alan P. Venook, Lawrence Fong

Phase II trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC).

Journal of Clinical Oncology

Robin Kate Kelley, Emily Mitchell, Spencer Behr, Jimmy Hwang, Bridget Keenan, Alexander Cheung, John Dozier Gordan, Andrew H. Ko, Pelin Cinar, Chloe Evelyn Atreya, Katherine Van Loon, Thomas Weber, Zoe Ngo, Zoe E. Quandt, Chienying Liu, Alan P. Venook, Lawrence Fong